Latest Vaccines News

GenVec Reports Inducement AwardGAITHERSBURG, Md., May 25, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) announced today that on May 23, 2012 it granted an option to purchase shares of its common stock to Cynthia Collins, its newly appointed President and Chief Executive Officer. The option grant was approved by the Compensation Committee of GenVec's Board of Directors and the Board of Directors, and was ma...

ImmunoCellular to list on NYSE:MKTBiotech firm ImmunoCellular Therapeutics (OTC:IMUC) reported that its common stock will now be listed on the New York stock Exchange, as the company seeks a broader investor base.The California-based company develops novel therapies to fight against...

ImmunoCellular Therapeutics Receives Approval for NYSE MKT ListingImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that its common stock has been approved for listing on the NYSE: MKT. Trading is expected to commence on the NYSE: MKT on Wednesday, May 30th, 2012 under the...

Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against RotavirusMerck (NYSE: MRK), known as MSD outside the United States and Canada, welcomes today’s launch in Rwanda of Africa’s first national rotavirus vaccination program with ROTATEQ® (rotavirus vaccine, live, oral, pentavalent), Merck’s vaccine for the prevention of rotavirus disease. Beginning today, the first infants will receive ROTATEQ at a health cente...

World Health Assembly endorses new plan to increase global access to vaccinesMinisters of Health from 194 countries at the Sixty-fifth World Health Assembly today endorsed a landmark Global Vaccine Action Plan (GVAP), a roadmap to prevent millions of deaths by 2020 through more equitable access to existing vaccines for people...

Rwanda Takes Major Step to Stem Child Diarrheal DeathsRwanda today accelerated its fight against rotavirus, the primary cause of deadly diarrhea in young children, when it became the fourth African country to introduce new rotavirus vaccines only recently made available to developing countries. Rotavirus is the primary cause of diarrhea in children. In Rwanda, diarrhea accounts for approximately 23% of child...

Merck welcomes launch of ROTATEQ in Rwanda of Africa’s rotavirus vaccination programMerck, known as MSD outside the United States and Canada, welcomes today's launch in Rwanda of Africa's first national rotavirus vaccination program with ROTATEQ (rotavirus vaccine, live, oral, pentavalent), Merck's vaccine for the prevention of rota...

PhRMA lays out positions as Japan considers health tech assessment and vaccines policiesAmid intensifying official discussions in Japan on various healthcare issues including a more formal methodology for health technology assessment (HTA), the US innovator industry association PhRMA has reiterated the need for a balanced.....

China Research Team Develops TB/HIV Combination VaccineA team of China researchers has developed a new DNA vaccine that simultaneously protected against tuberculosis and HIV in animal tests. M. tuberculosis is the cause of death in about 25% of all AIDS deaths. The disease is latent in many people; ho...

The ISHEID Meeting Makes a Donation of 2,500 Euros to The Berlin Patient, The First Man Cured from HIV/AIDSThe International Symposium on HIV & Emerging Infectious Diseases (ISHEID) currently held in Marseilles, France, is focused on a search for an HIV cure. Timothy Ray Brown, the "Berlin Patient" is the main star of it. Marseilles, France (PRWEB) May 25, 2012 HIV infection currently hits 34 millions individuals worldwide. It is therefore a top priority to find a vaccine for those who h...

immatics Wins 2012 TiE50 AwardTUEBINGEN, Germany, May 25, 2012 /PRNewswire/ -- immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has been named a 2012 TiE50 winner. These prestigious awards re...

New method can screen for bacterial genes that are expressed during meningitisBacterial meningitis is an infection of the meninges, the protective membrane that covers the spinal cord and brain. Children, elderly patients and immunocompromised patients are at a higher risk for the development of severe bacterial meningitis. Re...

Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae StrainsLA JOLLA, Calif., May 24, 2012 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company commercializing and developing genomic-driven solutions to solve a range of global challenges, today announced they have purchased an 81 acre site for scale up and testing of newly identified and engineered algal strains. The company will use the site, located in the Imperial Valley near the Salt...

Human medicines European Public Assessment Report (EPAR): Ixiaro, Japanese encephalitis vaccine (inactivated, adsorbed), Revision: 2, Authorised

Intercell plugs financing gap to sustainability with €35 millionAustrian vaccine developer Intercell has raised €15.2 million in a private equity placement and finalised a €20.0 million loan from BB Biotech. The money will finance the company through to "financial self-sustainability", it.....

Green ‘Pond Scum’ Holds Hope for Producing Edible Vaccine Against MalariaBiologists working on algal biofuelshave discovered another use for algae. They’ve found that these single-celled green factories are capable of inexpensively producing vaccines.

Study: DNA vaccine and duck eggs protect against hantavirus diseaseThe highly pathogenic hantavirus causes a condition known as hantavirus pulmonary syndrome (HPS), which has a case fatality rate of 35-40%. To help the fight against a disease that has no vaccine, U.S. Army scientists and industry collaborators h...

Human medicines European Public Assessment Report (EPAR): Nimenrix, meningococcal group A, C, W 135 and Y conjugate vaccine, Revision: 0, Authorised

Canine VacciCheck(R) Developed by Biogal was Highly Recommended in Articles Published in the Chicago Tribune and on BBC RadioKIBBUTZ GALED, Israel, May 24, 2012 /PRNewswire/ -- An interview recently published in the Chicago Tribune, addresses the use of Canine VacciCheck®, developed by Biogal, as a way to titer test dogs for core canine vaccines. In the article, Professor Schultz from the University of Wisconsin refers to Canine VacciCheck®: "One way to insure comfort for pet owners and veterinarians alike i...

HHS backs extended late-stage trial of Bavarian Nordic's ImvamuneBavarian Nordic said HHS supports an extended Phase III trial of smallpox vaccine Imvamune that would involve 4,000 participa -More-

Neovasc Inc. to present at Biofinance 2012 ConferenceTSX Venture Exchange: NVC VANCOUVER, May 24, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular disease, today announced that the company will present at the BioFinance 2012 Conference on May 30, 2012 at 2:00 pm EDT. The conference will be held at the St. Andrew's Club & Conference Centre in Toronto, Canada. Neovasc management will provide...

TEXT-S&P summary: SanofiSanofi's key business strengths include its critical mass in research and development (R&D) and marketing, which we view as key success factors for the pharmaceutical industry. This has enabled it to build up a substantial drug development pipe...

Experts, advocates urge continued funding for research into HIV, TB vaccines"[P]articipants at a symposium held last week by the U.K. Consortium on AIDS and International Development warned that progress on HIV and tuberculosis (TB) vaccines could be jeopardized by the recent downturn in global health funding," BMJ reports.

Immunovaccine Announces Financial Results for the Quarter Ended March 31, 2012 HALIFAX, NOVA SCOTIA -- (Marketwire) -- 05/24/12 -- Immunovaccine Inc. (TSX VENTURE: IMV) ("Immunovaccine" or the "Company"), a clinical stage vaccine company developing the patented DepoVax vaccine adjuvanting platform and product candidates for cancer therapy and infectious diseases, today released its financial and operational results for the quarter ended March 31, 2012. John Trizzino, CE...

Sirona Biochem to Present at BioFinance Conference VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 05/24/12 -- Sirona Biochem Corp. (TSX VENTURE: SBM)(PINKSHEETS: SRBCF)(FRANKFURT: ZSB), announced today it is confirmed to present at the upcoming BioFinance conference which is being held May 29-30, 2012. Sirona Biochem's presentation will be May 30th at 11:40am in Company Presentation Room 3. The company's Chief Business Officer, Sean Cunliffe, wil...

0 1 2 3 4 ›»

buy Vaccines market research data and corporate reports now Advertisement